- Home
- DTIL vs GANX Comparison
DTIL vs GANX Comparison
Compare DTIL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- GANX
- Stock Information
- Founded
- DTIL 2006
- GANX 2017
- Country
- DTIL United States
- GANX United States
- Employees
- DTIL N/A
- GANX N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- GANX Health Care
- Exchange
- DTIL Nasdaq
- GANX Nasdaq
- Market Cap
- DTIL 44.1M
- GANX 41.9M
- IPO Year
- DTIL 2019
- GANX 2021
- Fundamental
- Price
- DTIL $4.51
- GANX $1.64
- Analyst Decision
- DTIL Strong Buy
- GANX Strong Buy
- Analyst Count
- DTIL 2
- GANX 5
- Target Price
- DTIL $39.50
- GANX $7.60
- AVG Volume (30 Days)
- DTIL 104.8K
- GANX 203.8K
- Earning Date
- DTIL 11-04-2024
- GANX 11-14-2024
- Dividend Yield
- DTIL N/A
- GANX N/A
- EPS Growth
- DTIL N/A
- GANX N/A
- EPS
- DTIL 1.45
- GANX N/A
- Revenue
- DTIL $75,096,000.00
- GANX N/A
- Revenue This Year
- DTIL $50.33
- GANX N/A
- Revenue Next Year
- DTIL N/A
- GANX N/A
- P/E Ratio
- DTIL $3.21
- GANX N/A
- Revenue Growth
- DTIL 43.62
- GANX N/A
- 52 Week Low
- DTIL $4.56
- GANX $0.89
- 52 Week High
- DTIL $19.43
- GANX $5.33
- Technical
- Relative Strength Index (RSI)
- DTIL 24.26
- GANX 42.64
- Support Level
- DTIL $5.12
- GANX $1.59
- Resistance Level
- DTIL $6.18
- GANX $1.70
- Average True Range (ATR)
- DTIL 0.46
- GANX 0.15
- MACD
- DTIL -0.13
- GANX 0.00
- Stochastic Oscillator
- DTIL 5.21
- GANX 19.74
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.